Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Unknown statusPhase 4NCT01397994
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is to determine the anti-anginal and anti-ischemic effect of k-channel opener, nicorandil in patients of chronic stable angina.
Study details
- Official title
- A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina.
- Conditions
- Interventions
- Drug: Nicorandil
- Drug: Atenolol
- Sponsor
- Ferozsons Laboratories Ltd.
- Start date
- 2011-09
- Primary completion
- 2012-01
- Sex
- All
- Age range
- from 25 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Pakistan
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Patients of chronic stable angina with abnormal Exercise Myocardial Perfusion Spect Scan with reversible and partially reversible ischemic changes. 2. Male and female 3. Age 25 to 65 years 4. Patient must understand and be willing, able and likely to comply with all study procedures and restrictions and comprehends the diary cards. 5. Patient must be able to give voluntary written informed consent. Exclusion Criteria: 1. Hypertension of \> 170/100 mm of Hg 2. Valvular heart disease and cardiomyopathy 3. Myocardial infarction in \< 6 months 4. Unstable angina 5. Congestive cardiac failure 6. Severe anemia (Hb 7G/dl) 7. Cardiac arrhythmias or II or III degree AV block 8. Significant liver or renal dysfunction 9. IDDM (Type-1 diabetes mellitus) 10. Systolic blood pressure \< 100 mm Hg 11. Pregnant and nursing women 12. Known hypersensitivity to nicorandil 13. On calcium channel blockers 14. Patients not eligible for Tc 99m SPECT 15. Patients in whom beta blockers are contraindicated 16. Geographical inaccessibility for treatment or follow-up evaluations
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01397994